Biotech

All Articles

After a challenging year, Exscientia folds into Recursion

.After a year specified by pipe cuts, the departure of its own chief executive officer and also disc...

Cullinan, after $25M package, restore bispecific to Harbour

.Cullinan Therapeutics was actually excited sufficient with Port BioMed's bispecific immune system a...

A closer look at Fierce Biotech's Ferocious 15

.Within this week's incident of "The Top Pipe," our company are actually diving into Strong Biotech'...

Lilly faces stage 2 breakdown of tau-targeting med

.The confetti is actually still flying from Eli Lilly's party celebrating the commendation of Alzhei...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of significant leadership hirings, firings as...

Lykos will certainly ask FDA to reassess its own selection complying with denial of MDMA therapy for trauma

.Observing a bad presenting for Lykos Therapies' MDMA applicant for post-traumatic stress disorder a...

AN 2 one-halfs head count, ceases stage 3 trial after information dissatisfy

.AN2 Therapies is actually re-thinking its own organization in reaction to poor midphase information...

Merck pays out $700M for bispecific, spying autoimmune opening and also odds to test Amgen in cancer

.Merck &amp Co. is actually paying $700 thousand upfront to challenge Amgen in a blood cancer market...

Gilead pays J&ampJ $320M to go out licensing offer for seladelpar

.With Gilead Sciences about to an FDA decision for its own liver ailment medication seladelpar, the ...

' All palms on deck' at Lilly as peers target weight problems market

.CEO David Ricks may see the firms setting up camping tents at basecamp responsible for Eli Lilly in...